{
  "symbol": "UNH",
  "year": 2022,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1978,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.257
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 24,612 $ 21,375 Short-term investments 3,352 2,532 Accounts receivable, net 18,718 14,216 Other current receivables, net 12,439 13,866 Assets under management 4,017 4,449 Prepaid expenses and other current assets 5,218 5,320 Total current assets 68,356 61,758 Long-term investments 42,427 43,114 Property, equipment and capitalized software, net 9,421 8,969 Goodwill 84,159 75,795 Other intangible assets, net 11,285 10,044 Other assets 14,524 12,526 Total assets $ 230,172 $ 212,206 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 28,978 $ 24,483 Accounts payable and accrued liabilities 25,145 24,643 Short-term borrowings and current maturities of long-term debt 5,592 3,620 Unearned revenues 2,212 2,571 Other current liabilities 26,771 22,975 Total current liabilities 88,698 78,292 Long-term debt, less current maturities 45,799 42,383 Deferred income taxes 2,581 3,265 Other liabilities 11,967 11,787 Total liabilities 149,045 135,727 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,922 1,434 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 935 and 941 issued and outstanding 10 10 Retained earnings 80,540 77,134 Accumulated other comprehensive loss ( 7,730 ) ( 5,384 ) Nonredeemable noncontrolling interests 3,385 3,285 Total equity 76,205 75,045 Total liabilities, redeemable noncontrolling interests and equity $ 230,172 $ 212,206 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2022 2021 2022 2021 Revenues: Premiums $ 63,896 $ 56,233 $ 127,966 $ 111,719 Products 9,496 8,433 18,836 16,773 Services 6,645 6,099 13,017 12,017 Investment and other income 295 556 662 1,008 Total revenues 80,332 71,321 160,481 141,517 Operating costs: Medical costs 52,093 46,546 104,616 91,450 Operating costs 11,709 10,359 23,110 20,582 Cost of products sold 8,596 7,660 17,083 15,232 Depreciation and amortization 802 778 1,590 1,536 Total operating costs 73,200 65,343 146,399 128,800 Earnings from operations 7,132 5,978 14,082 12,717 Interest expense ( 467 ) ( 410 ) ( 900 ) ( 807 ) Earnings before income taxes 6,665 5,568 13,182 11,910 Provision for income taxes ( 1,466 ) ( 1,196 ) ( 2,835 ) ( 2,560 ) Net earnings 5,199 4,372 10,347 9,350 Earnings attributable to noncontrolling interests ( 129 ) ( 106 ) ( 250 ) ( 222 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,070 $ 4,266 $ 10,097 $ 9,128 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 5.41 $ 4.52 $ 10.75 $ 9.66 Diluted $ 5.34 $ 4.46 $ 10.61 $ 9.55 Basic weighted-average number of common shares outstanding 937 944 939 945 Dilutive effect of common share equivalents 13 12 13 11 Diluted weighted-average number of common shares outstanding 950 956 952 956 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 3 1 3 2 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2022 2021 2022 2021 Net earnings $ 5,199 $ 4,372 $ 10,347 $ 9,350 Other comprehensive (loss) income: Gross unrealized (losses) gains on investment securities during the period ( 1,331 ) 251 ( 3,354 ) ( 513 ) Income tax effect 304 ( 58 ) 769 116 Total unrealized (losses) gains, net of tax ( 1,027 ) 193 ( 2,585 ) ( 397 ) Gross reclassification adjustment for net realized gains included in net earnings ( 1 ) ( 9 ) ( 4 ) ( 16 ) Income tax effect \u2014 2 1 4 Total reclassification adjustment, net of tax ( 1 ) ( 7 ) ( 3 ) ( 12 ) Total foreign currency translation (losses) gains ( 676 ) 554 242 137 Other comprehensive (loss) income ( 1,704 ) 740 ( 2,346 ) ( 272 ) Comprehensive income 3,495 5,112 8,001 9,078 Comprehensive income attributable to noncontrolling interests ( 129 ) ( 106 ) ( 250 ) ( 222 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 3,366 $ 5,006 $ 7,751 $ 8,856 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2022 939 $ 10 $ \u2014 $ 78,782 $ ( 1,137 ) $ ( 4,889 ) $ 3,362 $ 76,128 Net earnings 5,070 94 5,164 Other comprehensive loss ( 1,028 ) ( 676 ) ( 1,704 ) Issuances of common stock, and related tax effects 1 \u2014 174 174 Share-based compensation 194 194 Common share repurchases ( 5 ) \u2014 ( 733 ) ( 1,767 ) ( 2,500 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,545 ) ( 1,545 ) Redeemable noncontrolling interests fair value and other adjustments 365 365 Acquisition and other adjustments of nonredeemable noncontrolling interests 12 12 Distribution to nonredeemable noncontrolling interests ( 83 ) ( 83 ) Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 Balance at March 31, 2021 944 $ 10 $ \u2014 $ 71,220 $ 741 $ ( 5,567 ) $ 2,909 $ 69,313 Net earnings 4,266 88 4,354 Other comprehensive income 186 554 740 Issuances of common stock, and related tax effects 2 \u2014 292 292 Share-based compensation 158 158 Common share repurchases ( 3 ) \u2014 ( 221 ) ( 1,029 ) ( 1,250 ) Cash dividends paid on common shares ($ 1.45 per share) ( 1,367 ) ( 1,367 ) Redeemable noncontrolling interests fair value and other adjustments ( 229 ) ( 229 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 85 85 Distribution to nonredeemable noncontrolling interests ( 74 ) ( 74 ) Balance at June 30, 2021 943 $ 10 $ \u2014 $ 73,090 $ 927 $ ( 5,013 ) $ 3,008 $ 72,022 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Nonredeemable Noncontrolling Interests Total Equity Six months ended June 30, (in millions) Shares Amount Net Unrealized Gains (Losses) on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2022 941 $ 10 $ \u2014 $ 77,134 $ 423 $ ( 5,807 ) $ 3,285 $ 75,045 Net earnings 10,097 182 10,279 Other comprehensive (loss) income ( 2,588 ) 242 ( 2,346 ) Issuances of common stock, and related tax effects 4 \u2014 507 507 Share-based compensation 476 476 Common share repurchases ( 10 ) \u2014 ( 1,217 ) ( 3,783 ) ( 5,000 ) Cash dividends paid on common shares ($ 3.10 per share) ( 2,908 ) ( 2,908 ) Redeemable noncontrolling interests fair value and other adjustments 234 234 Acquisition and other adjustments of nonredeemable noncontrolling interests 103 103 Distribution to nonredeemable noncontrolling interests ( 185 ) ( 185 ) Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 Balance at January 1, 2021 946 $ 10 $ \u2014 $ 69,295 $ 1,336 $ ( 5,150 ) $ 2\n) $ 11,910 15 Table of Contents ITEM\u00a02.",
      "score": 0.9987
    },
    {
      "sent": "23 Table of Contents The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2022 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2022 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 559 $ 215 $ (3,073) $ (7,035) 1 280 107 (1,583) (3,824) (1) (248) (107) 1,666 4,595 (2) (248) (191) 3,380 10,165 Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2022, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income and the full 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero.",
      "score": 0.9856
    },
    {
      "sent": "23 Table of Contents The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2022 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2022 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 559 $ 215 $ (3,073) $ (7,035) 1 280 107 (1,583) (3,824) (1) (248) (107) 1,666 4,595 (2) (248) (191) 3,380 10,165 Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2022, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income and the full 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero.",
      "score": 0.9856
    }
  ],
  "top_negative": [
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "17 Table of Contents RESULTS SUMMARY The following table summarizes our consolidated results of operations and other financial information: (in millions, e\noutlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We will continue seeking to balance growth and profitability across all these dimensions."
  ],
  "curated_text": "Symbol: UNH. Year: 2022. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 24,612 $ 21,375 Short-term investments 3,352 2,532 Accounts receivable, net 18,718 14,216 Other current receivables, net 12,439 13,866 Assets under management 4,017 4,449 Prepaid expenses and other current assets 5,218 5,320 Total current assets 68,356 61,758 Long-term investments 42,427 43,114 Property, equipment and capitalized software, net 9,421 8,969 Goodwill 84,159 75,795 Other intangible assets, net 11,285 10,044 Other assets 14,524 12,526 Total assets $ 230,172 $ 212,206 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 28,978 $ 24,483 Accounts payable and accrued liabilities 25,145 24,643 Short-term borrowings and current maturities of long-term debt 5,592 3,620 Unearned revenues 2,212 2,571 Other current liabilities 26,771 22,975 Total current liabilities 88,698 78,292 Long-term debt, less current maturities 45,799 42,383 Deferred income taxes 2,581 3,265 Other liabilities 11,967 11,787 Total liabilities 149,045 135,727 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,922 1,434 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 935 and 941 issued and outstanding 10 10 Retained earnings 80,540 77,134 Accumulated other comprehensive loss ( 7,730 ) ( 5,384 ) Nonredeemable noncontrolling interests 3,385 3,285 Total equity 76,205 75,045 Total liabilities, redeemable noncontrolling interests and equity $ 230,172 $ 212,206 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2022 2021 2022 2021 Revenues: Premiums $ 63,896 $ 56,233 $ 127,966 $ 111,719 Products 9,496 8,433 18,836 16,773 Services 6,645 6,099 13,017 12,017 Investment and other income 295 556 662 1,008 Total revenues 80,332 71,321 160,481 141,517 Operating costs: Medical costs 52,093 46,546 104,616 91,450 Operating costs 11,709 10,359 23,110 20,582 Cost of products sold 8,596 7,660 17,083 15,232 Depreciation and amortization 802 778 1,590 1,536 Total operating costs 73,200 65,343 146,399 128,800 Earnings from operations 7,132 5,978 14,082 12,717 Interest expense ( 467 ) ( 410 ) ( 900 ) ( 807 ) Earnings before income taxes 6,665 5,568 13,182 11,910 Provision for income taxes ( 1,466 ) ( 1,196 ) ( 2,835 ) ( 2,560 ) Net earnings 5,199 4,372 10,347 9,350 Earnings attributable to noncontrolling interests ( 129 ) ( 106 ) ( 250 ) ( 222 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,070 $ 4,266 $ 10,097 $ 9,128 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 5.41 $ 4.52 $ 10.75 $ 9.66 Diluted $ 5.34 $ 4.46 $ 10.61 $ 9.55 Basic weighted-average number of common shares outstanding 937 944 939 945 Dilutive effect of common share equivalents 13 12 13 11 Diluted weighted-average number of common shares outstanding 950 956 952 956 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 3 1 3 2 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2022 2021 2022 2021 Net earnings $ 5,199 $ 4,372 $ 10,347 $ 9,350 Other comprehensive (loss) income: Gross unrealized (losses) gains on investment securities during the period ( 1,331 ) 251 ( 3,354 ) ( 513 ) Income tax effect 304 ( 58 ) 769 116 Total unrealized (losses) gains, net of tax ( 1,027 ) 193 ( 2,585 ) ( 397 ) Gross reclassification adjustment for net realized gains included in net earnings ( 1 ) ( 9 ) ( 4 ) ( 16 ) Income tax effect \u2014 2 1 4 Total reclassification adjustment, net of tax ( 1 ) ( 7 ) ( 3 ) ( 12 ) Total foreign currency translation (losses) gains ( 676 ) 554 242 137 Other comprehensive (loss) income ( 1,704 ) 740 ( 2,346 ) ( 272 ) Comprehensive income 3,495 5,112 8,001 9,078 Comprehensive income attributable to noncontrolling interests ( 129 ) ( 106 ) ( 250 ) ( 222 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 3,366 $ 5,006 $ 7,751 $ 8,856 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2022 939 $ 10 $ \u2014 $ 78,782 $ ( 1,137 ) $ ( 4,889 ) $ 3,362 $ 76,128 Net earnings 5,070 94 5,164 Other comprehensive loss ( 1,028 ) ( 676 ) ( 1,704 ) Issuances of common stock, and related tax effects 1 \u2014 174 174 Share-based compensation 194 194 Common share repurchases ( 5 ) \u2014 ( 733 ) ( 1,767 ) ( 2,500 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,545 ) ( 1,545 ) Redeemable noncontrolling interests fair value and other adjustments 365 365 Acquisition and other adjustments of nonredeemable noncontrolling interests 12 12 Distribution to nonredeemable noncontrolling interests ( 83 ) ( 83 ) Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 Balance at March 31, 2021 944 $ 10 $ \u2014 $ 71,220 $ 741 $ ( 5,567 ) $ 2,909 $ 69,313 Net earnings 4,266 88 4,354 Other comprehensive income 186 554 740 Issuances of common stock, and related tax effects 2 \u2014 292 292 Share-based compensation 158 158 Common share repurchases ( 3 ) \u2014 ( 221 ) ( 1,029 ) ( 1,250 ) Cash dividends paid on common shares ($ 1.45 per share) ( 1,367 ) ( 1,367 ) Redeemable noncontrolling interests fair value and other adjustments ( 229 ) ( 229 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 85 85 Distribution to nonredeemable noncontrolling interests ( 74 ) ( 74 ) Balance at June 30, 2021 943 $ 10 $ \u2014 $ 73,090 $ 927 $ ( 5,013 ) $ 3,008 $ 72,022 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Nonredeemable Noncontrolling Interests Total Equity Six months ended June 30, (in millions) Shares Amount Net Unrealized Gains (Losses) on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2022 941 $ 10 $ \u2014 $ 77,134 $ 423 $ ( 5,807 ) $ 3,285 $ 75,045 Net earnings 10,097 182 10,279 Other comprehensive (loss) income ( 2,588 ) 242 ( 2,346 ) Issuances of common stock, and related tax effects 4 \u2014 507 507 Share-based compensation 476 476 Common share repurchases ( 10 ) \u2014 ( 1,217 ) ( 3,783 ) ( 5,000 ) Cash dividends paid on common shares ($ 3.10 per share) ( 2,908 ) ( 2,908 ) Redeemable noncontrolling interests fair value and other adjustments 234 234 Acquisition and other adjustments of nonredeemable noncontrolling interests 103 103 Distribution to nonredeemable noncontrolling interests ( 185 ) ( 185 ) Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 Balance at January 1, 2021 946 $ 10 $ \u2014 $ 69,295 $ 1,336 $ ( 5,150 ) $ 2\n) $ 11,910 15 Table of Contents ITEM\u00a02. 23 Table of Contents The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2022 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2022 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 559 $ 215 $ (3,073) $ (7,035) 1 280 107 (1,583) (3,824) (1) (248) (107) 1,666 4,595 (2) (248) (191) 3,380 10,165 Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2022, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income and the full 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero. 23 Table of Contents The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2022 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2022 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 559 $ 215 $ (3,073) $ (7,035) 1 280 107 (1,583) (3,824) (1) (248) (107) 1,666 4,595 (2) (248) (191) 3,380 10,165 Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2022, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income and the full 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero. Top negative sentences: By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Forward-looking snippets: Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). We will continue seeking to balance growth and profitability across all these dimensions. We expect broad-based competition to continue as the industry adapts to individual and employer needs. 17 Table of Contents RESULTS SUMMARY The following table summarizes our consolidated results of operations and other financial information: (in millions, e\noutlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). We will continue seeking to balance growth and profitability across all these dimensions."
}